In a prospective study of 35 ITP patients, including 16 multirefractory cases, platelet responses were observed in 66.7% of patients treated with oseltamivir combined with TPO-RA or immunosuppressive drugs, compared with 40% in oseltamivir monotherapy group (74). The gene discussed is TPO; the disease is rheumatoid arthritis.